We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...

Pemphigus vulgaris is a persistent immune system illness affecting a small number of people. Blisters form on the skin and in the mouth as a result. Although treatment and diagnosis might aid in ...

In 2024, revenue from Dupixent represented just under 32% ... alongside a rare skin condition called bullous pemphigoid (27,000 patients worldwide). The FDA is currently reviewing its safety ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN). has reached an unprecedented milestone as its stock soared to an all-time high of... ByInvesting.com • Aug 26, 2024 Regeneron shares reiterated at ...

Sanofi stock forms a Golden Cross, signaling bullish momentum as Dupixent nears FDA approval for bullous pemphigoid. SNY’s technicals remain strong, with all key moving averages trending higher ...

and Sanofi are seeking a label expansion for the drug to treat a rare skin disease called bullous pemphigoid. If approved, Dupixent would become the first targeted drug in this narrow indication ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...